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4. Expected results 
• Vesicles, CTB-modified and LPS-modified, were produced correctly and no problems showed up. 
• Results showed high levels of antibodies Anti-LPS O1 (Inaba and Ogawa), anti-LPS O139, anti-capsular 
O139 and anti-CTB. 
• All immunization groups induced a robust and long immune response with similar levels of Ig titers 
against both serogroups. 
• The protective efficacy of anti-LPS antibodies is mediated either through vibriocidal activity or 
inhibition of adhesion to the epithelial surface. 
• Only one dose was required  and the protection was always 97% in mice. 
• The vaccine shelf life was 5 years and storage temperature should be between 2-8°C. But the 
antigenicity of OMVs is not significantly compromised after prolonged heating, the viability was 60 
days.7 




5. Benefits of the project 
We need cholera vaccine because cholera is endemic in developing countries. Although the provision 
and establishment of safe water, food, and sanitation systems are the principal way to prevent 
cholera, these measures cannot be implemented in the near future in most areas where there is 
cholera. It’s known that V. cholerae shows increased resistance to antibiotics, complicating clinical 
management. These concerns and the improved protection of new-generation oral cholera vaccines 
have an importance in order to reduce cholera cases, alongside traditional cholera prevention 
measures. 
6. Work diffusion 
Regardless of whether the applicant group intends to publish the results in more impact journals in 
endemic areas, it's expected that the above results could be useful for professional sectors companies 
or users.  






































The principal objective is develop a new oral cholera vaccine, which would gives more protection to prevent the disease of cholera, inducing strong immune response, than  prequalification oral vaccines.  
1. Antecedents  
Cholera is an acute secretory diarrhoea disease caused by intestinal infection with Vibrio cholerae. Its estimated cholera affects 3–5 million people with 100,000 dead each year, around the world.1 Infection is 
usually asymptomatic or mild, but sometimes can be severe. Approximately 5% of infected people develop severe cholera and without treatment, over 50% of people can die in a few hours. Cholera has probably 
existed on the Indian subcontinent for thousands of years. From 1817 cholera has caused seven important pandemics around the world, with thousands deads.2 The transmission happens when food and water are 
contaminated through the faeces of infect people. Complications of cholera are causatives by the loss of fluids and electrolytes. Cholera’s treatment consists only of quickly oral fluid replacement.  But as it 
happened in the past, cholera remains largely a disease of impoverishment, where sanitation water is inappropriate or absent, social unrest and displacement, and continues to be a disease of major public health 
concern. 
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V. cholerae is Gram-negative proteobacteria, 
comma-shaped, facultative anaerobic, with a single 
polar flagellum. V. cholerae have two types or 
serogroups where only two, are O1 and O139, can 
be epidemics, because they have the ability to 
produce choleric toxins.  
Genome of V. cholerae has two pathogenic islands, 
where the genome has been lysogenized with a 
filamentous phage. It contains regulatory and 
virulence factors, such as ctxA and ctxB (cholera 
toxin genes), that help  the pathogen colonization 
and toxin expression (figure 1).3 
Figure 1: The action of cholera enterotoxin. Cholera toxin is a heat-
stable AB enterotoxin that activates a second messenger pathway, 
disrupting normal ion flow in the intestine.2 
Currently, there are three 
prequalification oral vaccines for the 
World Health Organization (WHO), 
described in table 1. Duration of 
protection is the first problem we can 
see, it’s less than two years long and less 
than 90% of protection. In addition there 
are other troubles like storage, price, 
shelf life and presentation where is 
required an intervention. 
Table 1: Comparison of killed WC-rCTB vaccine, live CVD-
HgR vaccine and reformulated WC-only vaccine.2,5,6  
Figure 2: Schematic diagram showing gut defences and 
serum immune responses against V. cholerae infection.4  
Lipopolysaccharides and cholera toxin 
are virulence factors, which are 
important for the immune response, 
concretely humoral immunity (figure 2). 
Cholera toxin induces sIgA, which 
neutralizes pathogens of intraluminal 
mucus. LPS induce IgA and IgM, which 
plays an important role in affinity 
maturation IgG, important for the 
development of memory B cells. 
A new oral recombinant vaccine was synthesized by outer membrane vesicles derived 
from V.  Cholerae. The idea is to use a method that can present LPS-modified with CTB-
modified and it gives protection against both clinically relevant serogroups. These 
vesicles consist of outer membrane lipids, a subset of outer membrane proteins and 
soluble periplasmic components (figure 4).7 
Control, checking live-cell 
contamination 
Vesicles were  resuspended in 
buffer,  filtered and mixed 
Final vaccine 
5. Centrifugation 
and filtration of 
the supernatant. 
• pCTB  ctb-modified + β-lactomase gene + KmR 
• pLPS  msbB-modified + TetR 
• pCTB  ctb-Modified + β-lactomase gene derived + KmR 
• pLPS  msbB-Modified + TetR  













E. coli E. coli E. coli 
Figure 4: Model of vesicle biogenesis. OM vesicles are 
proteoliposomes consisting of OM phospholipids and LPS, a subset 
of OM proteins, and periplasmic proteins.8 
4.High Tº selection was applied to obtain Amps colonies 
and correct resistant deletions, by recombinase, were 
confirmed by PCR. 
2. Objective 
6. Work iff i  
5. fits of the project . Expected results 
Characteristic WC-rCTB CVD103-HgR Reformulated WC-only 
Commercial name Dukoral® Orochol® or Mutachol® Vietnam: mORCVAX® 
India: Shanchol® 
Vaccine type Killed whole cells of V. cholerae 
O1 plus CTB recombinant  
Live attenuated V. 
cholerae. 
Killed whole cells of V. 
cholerae O1. 
Vaccine composition Inaba Cairo 48 Classical and 
Ogawa Cairo 50 Classical (heat-
killed), Inaba Phil 6973 El Tor 
and Ogawa Cairo 50 Classical 
(formalin killed) 
Inaba Classical strain 
596B 
Ogawa Cairo 48/50 
Classical (heater-killed). 
Inaba Phil6973 El Tor, 
Ogawa Cairo 50 Classical 
and 4260B O139 (formalin 
killed) 
Administration Route Oral Oral  Oral 
Formulation Liquid Lyophilized Liquid 
Regimen 2 doses  1 dose 2 doses  
Age range for 
vaccination 
≥ 2 years ≥ 2 years Vietnam: ≥ 2 years 
India: ≥ 1 year 
Duration of protection 2 years  ≥ 6 months  At least 3 years 
Buffer requirement  Yes  Yes  No 
Storage temperature 2° to 8° C 2° to 8° C 2° to 8° C 
Shelf life 3 years  2 years 2 years 
International 
acceptance 
WHO-prequalified Was WHO-prequalified 
until 2004  
WHO-prequalified 
Price to the public 
sector per dose 
~$5.25/dose for small quantity 
of 250.000 doses 
Vaccine not currently 
available 
Vietnam: ~$0.75/dose 
India: $1.85 per dose 
Protection 1st/2nd year 80%/60% 91% only six months 69%/50% 
 
7. Bibliography 
3. Conjugation and homologous recombination. 
1. To construct the thermosensitive suicide plasmids 
pCTB/pLPS/pCAP, upstream and downstream fragments 
of the gene were PCR-amplified using the oligonucleotide 
pairs digested with the appropriate restriction enzyme, 
and finally ligated into the digested pCTB/pLPS/pCAP 
(figure3). Deletion mutants were generated using 
derivatives of the suicide vector pCTB/pLPS7pCAP.7 
Plasmids are carrying AmpR and recombinase. 
2. Obtaining our plasmids and confirmation by PCR. 
Figure 3: Schematic figure of one study that have shown 
the deletion of mshA by PCR and construction of suicide 
vector pCVDmshA.8 
Abbreviations: 
pCTB: Modified ctxB gene fused to the type 2 secretion 
signal sequence (derived from the β-lactamase gene). 
pLPS: Truncated msbB (lacks a typical lipid A structure). 
pCAP: Mutant otnA (alteration transporter of capsule 
precursors).  
